Banco Bilbao Vizcaya Argentaria S.A. Buys 137 Shares of Eli Lilly and Company (NYSE:LLY)

Banco Bilbao Vizcaya Argentaria S.A. grew its stake in Eli Lilly and Company (NYSE:LLY) by 0.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 35,229 shares of the company’s stock after buying an additional 137 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Eli Lilly and Company were worth $27,204,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in LLY. Highline Wealth Partners LLC raised its holdings in Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock valued at $35,000 after acquiring an additional 20 shares in the last quarter. FPC Investment Advisory Inc. raised its stake in shares of Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after purchasing an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. bought a new position in Eli Lilly and Company in the fourth quarter worth $48,000. Compass Financial Services Inc acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $50,000. Finally, Fiduciary Advisors Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter worth about $58,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY stock opened at $830.57 on Thursday. The company has a 50 day moving average price of $826.81 and a 200 day moving average price of $819.07. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a market capitalization of $787.52 billion, a PE ratio of 70.93, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LLY. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research report on Friday, January 17th. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and lowered their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Morgan Stanley cut their price objective on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating for the company in a report on Wednesday, April 9th. Finally, Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a report on Tuesday. They issued an “overweight” rating and a $975.00 target price on the stock. Two analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,017.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.